[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscle-health\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscle-health":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,58,98,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100633575","the-effects-of-peptistrong-and-whey-on-muscle-function-in-older-adults-100633575",false,"NCT07528469","The Effects of PeptiStrong and Whey on Muscle Function In Older Adults","The Effects of PeptiStrong and Low Dose Whey Protein Versus High Dose Whey Protein Alone on Muscle Function In Older Adults","Inclusion Criteria:\n\n* Men and women aged 60 to 85 years at the time of enrolment\n* Community-dwelling (living independently or with minimal assistance)\n* Able to walk independently (with or without a walking aid) and complete simple physical function tests (such as standing up from a chair and walking short distances)\n* Willing and able to attend two study visits at the research facility (baseline and end of study)\n* Willing and able to consume a protein drink containing whey protein (derived from milk) once daily for 30 days\n* Able to understand the study information and provide written informed consent\n\nExclusion Criteria:\n\n* Any known food allergy or intolerance to fava bean protein or milk protein\n* Diagnosed kidney disease or any medical condition where increased protein intake is contraindicated\n* Yes to any of the answers on the \"Older Adult Functional Assessment Screening Questionnaire\"\n* Individuals with implanted electronic devices\n* Current or recent (within the past 3 months) participation in another clinical research study involving a nutritional or exercise intervention\n* Conditions that significantly impair mobility or balance such that safe completion of the physical function tests is not possible",true,"ALL","60 Years","85 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","Examining the effects of PeptiStrong and protein on muscle function in older adults",[28,29,30,31,32,33,34],"Healthy Ageing","Protein Supplementation","Muscle Health","Muscle Function","Hand Grip Strength","Longevity","Peptides",[36,37,38,39,33,40,41,42,43,44],"Healthy Aging","Protein supplementation","Muscle function","Physical performance","Bioactive peptides","Hand grip strength","Short performance physical battery","Nuritas","Liverpool John Moore University","RECRUITING","2026-04-30",{"date":48,"type":49},"2026-05-06","ACTUAL",{"date":51,"type":49},"2026-04-06",{"date":53,"type":22},"2026-10-30",{"name":55,"class":56},"Nuritas Ltd","INDUSTRY",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":16,"sex":17,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":23,"phases":70,"briefSummary":71,"conditions":72,"keywords":78,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":97},"100621225","diet-synergy-in-muscle-protein-synthesis-100621225","NCT07367854","Diet Synergy in Muscle Protein Synthesis","Impact of Food Combinations on the Stimulation of Post-exercise Muscle Protein Synthesis in Healthy Adults","POTATO","Inclusion Criteria:\n\n* Age 19-40 yrs\n* Pre-menopausal\n* Recreationally-active\n* Weight stable for prior 6 months\n\nExclusion Criteria:\n\n* Age outside of range (20 - 35 yrs)\n* Pregnancy\n* Irregular menstrual cycles (i.e., \\~21 day or \\~35 day cycle)\n* Participation in previous research using L-\\[1-13C\\] leucine and L-\\[ring-2H5\\] phenylalanine\n* Participation in other ongoing research that interferes with this study (e.g., conflicting diet, activity interventions, etc.)","19 Years","40 Years",{"count":69,"type":22},15,[25],"In the present semi-crossover randomized design, 15 recreationally active young adults (19-40 y) will receive stable isotope tracer infusions and perform a single bout of resistance exercise. Immediately after exercise, participants will ingest either 1 medium russet potato with skins and 2 ounce-equivalent lean ground beef combination (274 kcals, 19.3 g protein, 5 g fat, 37 g carbohydrates, and 4 g fiber), 2 slices of white bread and beef combination (262 kcals, 19.8 g protein, 6.8 g fat, 28 g carbohydrates, and 1.8 g fiber) or 2 ounce-equivalent beef (93% lean meat\u002F7% fat; 110 kcals, 14.8 g protein, and 5 g fat). Repeated blood and muscle biopsies will be collected to determine whole body leucine kinetics, amino acid concentrations, anabolic signaling and myofibrillar protein synthesis rates during the trials.",[73,74,30,75,76,77],"Muscle Protein Synthetic Response to Protein","Muscle Protein Synthesis","Protein Metabolism","Recreational Activities","Isotope Labeling",[79,80,81,82,83,84,85,86],"protein","leucine kinetics","food matrix","protein synthesis","potato","stable isotope tracers","constant infusions","food combinations","2026-04-27",{"date":89,"type":49},"2026-05-01",{"date":91,"type":49},"2026-03-01",{"date":93,"type":22},"2028-11-01",{"name":95,"class":96},"University of Illinois at Urbana-Champaign","OTHER",2,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":16,"sex":17,"minAge":106,"maxAge":18,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":57},"100631610","dose-response-impact-of-geranylgeraniol-gg-supplementation-on-muscle-health-100631610","NCT07502924","Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscle Health","Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscular Strength, Body Composition, Sex Steroid Hormones and CoQ10 Levels in Healthy Men and Women","GGE","Inclusion Criteria:\n\n* Between 30 and 60 years old.\n* Body mass index values will range from \\>18.5 and \\\u003C29.9 kg\u002Fm2\n* Subject agrees to maintain their existing dietary patterns throughout the study period.\n* Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours prior to each test day.\n* Is physically active, defined as at least 30 min of moderate exercise on at least 4 days a week.\n* Avoid consumption of pomegranate juice and avoid consumption of CoQ10, vitamin B3 and its precursors, L-carnitine, MK-4\n* Subject is willing and able to comply with the study protocol.\n* Subject has given voluntary, written, informed consent to participate in the study.\n\nExclusion Criteria:\n\n* BMI \\\u003C18.5 or \\> 29.9 kg\u002Fm2\n* Positive medical history and\u002For is currently being treated for some form of heart disease, cardiovascular disease, kidney disease, renal failure, or has dialysis performed on regular intervals, Type I or Type II diabetes (determined as fasting blood glucose \\> 126 mg\u002FdL), thyroid disease, liver disease or some form of clinically diagnosed hepatic impairment, immune disorder (i.e., HIV\u002FAIDS), or neurological condition or disease.\n* Diagnosed with any affective disorder or other psychiatric disorder that required hospitalization in the prior year.\n* History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).\n* Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)\n* Genetic musculoskeletal and neurologic disorder known to affect skeletal muscle metabolism\n* Has donated blood in past 60 days\n* Diagnosed with or being treated for any endocrinological disorder and\u002For taking hormone boosting supplements (e.g. herbs) or hormone replacement therapy (prescribed\u002Fdoctor ordered or not)\n* Had CoQ10 supplement in past 30 days. Had steroid medication one month before starting the study\n* Currently prescribed for the first time a statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) and\u002For a hypertension medication (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, - Vasodilators, etc.) within the past 6 months or has had their dosage or medication changed within the past 6 months\n* Current smoker (average of \\> 1 pack per week within the past 3 months) or has quit within the past six months. This includes all forms of nicotine\n* Intake of any drugs (prescribed or over the counter) or dietary supplements that are known or are purported to impact energy expenditure or weight loss (caffeine doses \\\u003C300 mg\u002Fday is permissible)\n* Women with a history of hormone-related conditions such as endometriosis, fibroids, polycystic ovary syndrome\n* Women who are pregnant, planning to become pregnant, or lactating currently or within the past six months\n* Have a known sensitivity or allergy to any of the study products\n* History of alcohol or substance abuse in the 12 months prior to screening\n* Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol\n* Has participated in other clinical trials focused on physical and muscle performance within the last year\n* They plan major changes in lifestyle (i.e., diet, dieting, exercise level, travel, etc.) during the study\n* Individuals who regularly compete as part of sanctioned athletic activities or those individuals who regularly train more than 360 minutes of exercise per week\n* Recent history (\\\u003C3 months) of exercise training or weight loss (\\> 5%)\n* Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data","30 Years",{"count":108,"type":22},70,[25],"This study will evaluate the effects of daily geranylgeraniol (GG) supplementation on muscular strength, body composition, and aerobic capacity in healthy, physically active men and women. Approximately 60 participants aged 30-60 years will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group trial lasting 8 weeks.\n\nParticipants will be assigned to receive either placebo, 150 mg GG, or 300 mg GG daily. Outcome measures will be assessed at baseline, week 4, and week 8 and include maximal strength (1RM bench press and leg press), fat-free mass, muscular endurance, aerobic capacity (VO2peak), and circulating biomarkers related to metabolism and health.",[30,112,113],"Muscle Strength","Body Composition","2026-03-25",{"date":116,"type":49},"2026-03-31",{"date":118,"type":49},"2025-03-03",{"date":120,"type":22},"2026-08-01",{"name":122,"class":96},"Lindenwood University",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":130,"maxAge":4,"enrollmentInfo":131,"targetDuration":133,"studyType":134,"phases":4,"briefSummary":135,"conditions":136,"keywords":140,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":57},"100558161","bone-and-muscle-health-following-sleeve-gastrectomy-in-men-premenopausal-and-postmenopausal-women-100558161","NCT06547515","Bone and Muscle Health Following Sleeve Gastrectomy in Men, Premenopausal and Postmenopausal Women","BONUS","Inclusion Criteria:\n\n* Men and women aged \\>18 years;\n* Awaiting SG for the bariatric group or meeting the criteria for SG but not undergoing surgery for the non-surgical group.\n* Menopause: defined as the absence of menses for a year and a serum follicular-stimulating hormone (FSH) \\>40 UI\u002FL.\n* Women taking oral contraceptive pills or hormone replacement therapy\n* Patients with type 2 diabetes.\n\nExclusion Criteria:\n\n* Type 1 diabetes;\n* Disease (e.g., uncontrolled thyroid disease, Malabsorptive or overt inflammatory disorder)\n* Metabolic bone disease other than osteoporosis or type 2 diabetes,\n* Creatinine clearance \\\u003C30 ml\u002Fmin) or medication (e.g., glucocorticoids, anti-epileptic drugs, osteoporosis therapy, thiazolidinediones) affecting bone metabolism;\n* Weight \\>204 kg (DXA weight limit) or BMI \\>60 kg\u002Fm2 (upper limit to allow for QCT examination);\n* Current or planned pregnancy during follow-up; breast-feeding.","18 Years",{"count":132,"type":22},156,"36 Months","OBSERVATIONAL","Background: Bariatric surgery is gaining in popularity. While it's health benefits are undisputed, the older malabsorptive bariatric procedures (Roux-in-Y gastric bypass - RYGB and biliopancreatic diversion - BPD) are associated with an increased risk of fractures and falls as early as 3-5 years after surgery. Sleeve gastrectomy - SG is now the most performed bariatric procedure. Although SG does not cause malabsorption, it is predicted to result in bone and muscle loss via weight loss and weight loss-independent mechanisms. Primary aim: to compare the changes in spine volumetric bone mineral density (vBMD) by quantitative computed tomography (QCT) and muscle mass at mid-femur by computed tomography (CT) at 3 years in the 3 groups of: 1) men; 2) premenopausal women; 3) postmenopausal women after SG versus their respective non-surgical peers who did not undergo SG in the 3-year period following recruitment. Secondary aims: to compare the changes in vBMD by QCT at skeletal sites other than the spine and in areal bone mineral density (aBMD) by dual-energy X-ray absorptiometry (DXA), whole-body muscle mass by DXA, muscle quality by CT at mid-femur and muscle strength as well as in selected physical performance and capacity tests shown to predict falls and fractures between 0-1 and 1-3 years after SG in the same 3 groups after SG vs. in the respective non-surgical groups.",[137,138,139,30],"Bariatric Surgery","Bone Health","Severe Obesity",[141,142,139,30],"bariatric surgery","Bone health","2025-06-05",{"date":145,"type":49},"2025-06-10",{"date":147,"type":49},"2022-09-14",{"date":149,"type":22},"2026-08-15",{"name":151,"class":96},"CHU de Quebec-Universite Laval"]